Psychopharmacology: Ethnic and Cultural Perspectives

Psychiatry: Third Edition

Volumn 2, Issue , 2008, Pages 2112-2122

  Lin, Keh Ming ^a   Chen, Chia Hui ^a   Yu, Shu Han ^a   Lin, Margaret T ^b   Smith, Michael W ^c   Roose, Steven P ^d  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b KAISER PERMANENTE   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Cross cultural comparison; Ethnic groups; Psychopharmacology; Psychotropic drugs

Indexed keywords

EID: 84867375025     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470515167.ch100     Document Type: Chapter

References (60)

1. Acosta FX, Yamamoto J, and Evans LA (1982) Effective Psychotherapy for Low-Income and Minority Patients. Plenum Press, New York, USA.
2. Adebimpe VR (1981) Overview: White norms and psychiatric diagnosis of Black patients. American Journal of Psychiatry 138, 279-285.
3. Akullu E, Persson I, Bertilsson L, et al. (1996) Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. Journal of Pharmacology and Experimental Therapeutics 278, 441-446.
4. Allen JG, Rack P, and Vaddadi K (1977) Differences in the effects of clomipramine on English and Asian volunteers: Preliminary report on a pilot study. Postgraduate Medical Journal 53, 79-86.
5. Anderson KE and Kappas A (1991) Dietary regulation of cytochrome P450. Annual Review of Nutrition 11, 141-167.
6. Becker MH (1985) Patient adherence to prescribed therapies. Medical Care 23, 539-555.
7. 2 receptor gene variants: Association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics 5, 121-141.
8. Brosen K (1995) Drug interactions and the cytochrome P450 system. Clinical Pharmacokinetics 29, 20-25.
9. Buckalew LW and Coffield K (1982) Drug expectations associated with perceptual characteristics: Ethnic factors. Perceptual and Motor Skills 55, 915-918.
10. Castro, FG, Furth P, and Karlow H (1994) The health beliefs of Mexican, Mexican-American and Anglo-American women. Hispanic Journal of Behavioral Sciences 6, 365-383.
11. Chen YC, Lu RB, Peng GS, et al. (1999) Alcohol metabolism and cardiovascular response in an alcoholic patient homozygous for the ALDH2*2 variant gene allele. Alcoholism, Clinical and Experimental Research 23, 1853-1860.
12. Dai D, Tang J, Rose R, et al. (2001) Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos. Journal of Pharmacology and Experimental Therapeutics 299(3), 825-831.
13. D'Arcy PF(1991) Adverse reactions and interactions with herbal medicines. Part 1. Adverse reactions. Adverse Drug Reactions and Toxicological Reviews 10, 189-208.
14. Eisenberg DM, Davis RB, Ettner SL, et al. (1998) Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey. JAMA: The Journal of the American Medical Association 280, 1569-1575.
15. Eriksson CJ, Fukunaga T, Sarkola T, et al. (2001) Functional relevance of human ADH polymorphism. Alcoholism, Clinical and Experimental Research 25(5 Suppl ISBRA), 157S-163S.
16. Fugh-Berman A (2000) Herb-drug interactions. Lancet 355, 134-138.
17. Gillis L, Trollip D, Jakoet A, et al. (1987) Non-compliance with psychotropic medication. South African Medical Journal 72, 602-606.
18. Goldstein JA, Ishizaki T, Chiba K, et al. (1997) Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 7, 59-64.
19. Greenberg BD, McMahon FJ, and Murphy DL (1998) Serotonin transporter candidate gene studies in affective disorders and personality: Promises and potential pitfalls. Guest editorial. Molecular Psychiatry 3, 186-189.
20. Greenblatt DJ (1993) Basic pharmacokinetic principles and their application to psychotropic drugs. Journal of Clinical Psychiatry 54, 8-13.
21. Guengerich FP, Shimada T, Yun CH, et al. (1994) Interactions of ingested food, beverage, and tobacco components involving human cytochrome P4501A2, 2A6, 2E1, and 3A4 enzymes. Environmental Health Perspectives 102 (Suppl 9), 49-53.
22. Hietala J, West C, Syvalahti E, et al. (1994) Striatal D2 dopamine receptor binding characteristics in vivo in patients with alcohol dependence. Psychopharmacology 116, 285-290.
23. Hsieh KP, Lin YY, Cheng CL, et al. (2001) Novel mutations of CYP3A4 in Chinese. Drug Metabolism and Disposition: The Biological Fate of Chemicals 29(3), 268-273.
24. Ibeanu GC, Blaisdell J, Ferguson RJ, et al. (1999) A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin. Journal of Pharmacology and Experimental Therapeutics 290(2), 635-640.
25. Ibeanu GC, Goldstein JA, Meyer U, et al. (1998) Identification of new human CYP2C19 alleles (CYP2C19&6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin. Journal of Pharmacology and Experimental Therapeutics 286(3), 1490-1495.
26. Ingelman-Sundberg M (2005) Genetic polymorphism of cytochrome P450 2D6 (CYP2D6): Clinical consequences, evolutionary aspects and functional diversity. The Pharmacogenomics Journal 5, 6-13.
27. Jurima-Romet M, Crawford K, Cyr T, et al. (1994) Terfenadine metabolism in human liver: In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metabolism and Disposition: The Biological Fate of Chemicals 22, 849-857.
28. Kim H, Lim SW, Kim S, et al. (2006) Monoamine transporter gene polymorphisms and antidepressant response in Koreans with late-life depression. JAMA: The Journal of the American Medical Association 296, 1609-1618.
29. Kinirons MT and Crome P (1997) Clinical pharmacokinetic considerations in the elderly: An update. Clinical Pharmacokinetics 33, 302-312.
30. Kinzie JD, Leung P, Boehnlein J, et al. (1987) Tricyclic antidepressant plasma levels in Indochinese refugees: Clinical implication. Journal of Nervous and Mental Disease 175, 480-485.
31. Kirchheiner J and Seeringer A (2006) Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochimica et Biophysica Acta 1770(3), 489-494.
32. Kleinman A, Eisenberg L, and Good BJ (1978) Culture, illness, and care: Clinical lessons from anthropologic and cross-cultural research. Annals of Internal Medicine 88(2), 251-258.
33. Lee S, Wing YK, and Wong KC (1992) Knowledge and compliance towards lithium therapy among Chinese psychiatric patients in Hong Kong. Australian and New Zealand Journal of Psychiatry 26, 444-449.
34. Lin KM (1981) Traditional Chinese medical beliefs and their relevance for mental illness and psychiatry. In Normal and Abnormal Behavior in Chinese Culture, Kleinman S and Lin TY (eds). Reidel, Hingham, Dordrecht, Boston, MA, USA.
35. Lin KM, Demonteverde L, and Nuccio I (1990) Religion, healing and mental health among Filipino-Americans. International Journal of Mental Health 19, 40-44.
36. Lin KM and Poland RE (1995) Ethnicity, Culture, and Psychopharmacology. In Psychopharmacology: The Fourth Generation of Progress, Bloom FE and Kupfer DI (eds). Raven Press, New York, USA.
37. Lin KM, Poland RE, Lan JK, et al. (1988) Haloperidol and prolactin concentrations in Asians and Caucasians. Journal of Clinical Psychopharmacology 8, 195-201.
38. Lin KM, Poland RE, and Nakasaki G (1993) Psychopharmacology and Psychobiology of Ethnicity. American Psychiatric Press, Washington, DC, USA.
39. Lopez SR (1989) Patient variable biases in clinical judgment: Conceptual overview and methodological considerations. Psychological Bulletin 106, 184-203.
40. McLeod HL, Fang L, Luo X, etal. (1994) Ethnic differences in erythrocyte catechol-O-methyltransferase activity in black and white Americans. Journal of Pharmacology and Experimental Therapeutics 270, 26-29.
41. Mendoza R, Wan YJY, Poland RE, et al. (2001) CYP2D6 polymorphism in a Mexican American population. Clinical Pharmacology and Therapeutics 70(6), 552-560.
42. Mezzich JE, Kleinman A, Fabrega H, et al. (1995) Culture and Psychiatric Diagnosis. American Psychiatric Press, Washington, DC, USA.
43. National Institute of Mental Health (1997) Genetics and Mental Disorders: Report of the National Institute of Health's Genetics Workgroup. www.nimh.nih.gov/research/genetics.htm.
44. Nakajima M, Yodoi T, Mizutani M, et al. (1999) Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: Effect on the CYP1A2 inducibility in humans. Journal of Biochemistry (Tokyo) 125(4), 803-808.
45. Noble EP, Blum K, Ritchie T, et al. (1991) Allelic association of the D2 dopamine receptor gene with receptor-binding characteristics in alcoholism. Archives of General Psychiatry 48, 648-654.
46. Oesterheld J and Kallepalli BR (1997) Grapefruit juice and clomipramine: Shifting metabolic ratios. Journal of Clinical Psychopharmacology 17, 62-63.
47. Price N, Glazer WM, and Morgenstern H (1985) Race and the use of flu-phenazine decanoate. American Journal of Psychiatry 142, 1491-1492.
48. Raimundo S, Fischer J, Eischelbaum M, et al. (2000) Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 10(7), 577-581.
49. Rivera-Calimlim L and Reilly DK (1984) Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: Difference in levodopa tolerance. Clinical Pharmacology and Therapeutics 35, 804-809.
50. Ross P, Hall L, Smirnov I, et al. (1998) High level multiplex genotyping by MALDI-TOF mass spectrometry. Nature Biotechnology 16, 1347-1351.
51. 3 receptor genes in alcohol dependence. Psychiatric Genetics 5, 171-176.
52. Shimada T, Tsumura F, Yamazaki H, et al. (2001) Characterization of (+/-)-bufuralol hydroxylation activities in liver microsomes of Japanese and Caucasian subjects genotyped for CYP2D6. Pharmacogenetics 1(2), 143-156.
53. Sramek J, Roy S, Ahrens T, et al. (1991) Prevalence of tardive dyskinesia among three ethnic groups of chronic psychiatric patients. Hospital and Community Psychiatry 42, 590-592.
54. Stephens EA, Taylor JA, Kaplan N, et al. (1994) Ethnic variation in the CYP2E1 gene: polymorphism analysis of 695 African-Americans, Euro-pean-Americans and Taiwanese. Pharmacogenetics 4, 185-192.
55. Swartzman LC and Burkell J (1998) Expectations and the placebo effect in clinical drug trials: Why we should not turn a blind eye to unblinding, and other cautionary notes. Clinical Pharmacology and Therapeutics 64, 1-7.
56. Vandenbergh DJ, Persico AM, Hawkins AL, et al. (1992) Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 14, 1104-1106.
57. Wan YJY, Poland RE, Han G, et al. (2001) Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in Southern California. Pharmacogenetics 11, 489-499.
58. Weiss M (1997) Explanatory Model Interview Catalogue (EMIC): Framework for comparative study of illness. Transcultural Psychiatry 34, 235-263.
59. Xie HG, Stein CM, Kim RB, et al. (1999) Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 9, 539-49.
60. Yue QY, Bergquist C, and Gerden B (2000) Safety of St. John's Wort (Hypericum perforatum). The Lancet 355, 576-577.